CAM2029 (octreotide subcutaneous depot) clinical trials

A Phase 3, open-label, single-arm, multi-center trial to assess the long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

This study looks at a new way to give medicine for acromegaly, a condition caused by too much growth hormone. We want to see how safe this new treatment is over a long time and if it helps control the condition effectively. It's for adults with acromegaly.